Cellegy Pharmaceuticals

Cellegy reports loss of $0.04 per share

Published in Lab Business Week, September 24th, 2006

Cellegy Pharmaceuticals, Inc., (CLGY.OB) announced its second quarter 2006 financial results.

Revenues for the 3 months ended June 30, 2006 were $1,227,000 compared to $7,613,000 during the same period in 2005. Prior year revenues include $6.5 million in revenue realized in connection with the settlement of the PDI litigation.

Revenues for the 6 months ended June 30, 2006 were $2,463,000 compared to $9,066,000 for the same period in 2005. These included licensing revenues of $379,000 and $6,759,000 for the 6 months ended June 30, 2006 and 2005, respectively.

Research and development expenses for the 3 months ended June 30, 2006...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-09-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry